{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T15:40:07Z","timestamp":1754062807197,"version":"3.41.2"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":70,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.ctarc.2025.100898","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T15:25:19Z","timestamp":1741879519000},"page":"100898","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world comparative outcomes of EGFR-TKIs for first-line treatment of EGFR+ metastatic non\u2013small-cell lung cancer"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8676-7434","authenticated-orcid":false,"given":"Kibum","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakil","family":"Syeed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trang","family":"Au","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amber","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew B.","family":"Schabath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Cass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori","family":"Pai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenghui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Balmaceda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Autumn","family":"Carey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mumtu","family":"Lalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Henry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Brixner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Stenehjem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2025.100898_bib0001","first-page":"69","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ctarc.2025.100898_bib0002","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ctarc.2025.100898_bib0003","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0025-6196(11)60735-0","article-title":"Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship","volume":"83","author":"Molina","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.ctarc.2025.100898_bib0004","first-page":"1","article-title":"Epidermal growth factor receptor mutation (EGFR) testing for prediction of response to EGFR-targeting tyrosine kinase inhibitor (TKI) drugs in patients with advanced non-small-cell lung cancer: an evidence-based analysis","volume":"10","year":"2010","journal-title":"Ont. Health Technol. Assess. Ser."},{"key":"10.1016\/j.ctarc.2025.100898_bib0005","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1056\/NEJMe1714580","article-title":"Osimertinib as first-line treatment in EGFR-mutated non-small-cell lung cancer","volume":"378","author":"Popat","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2025.100898_bib0006","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2025.100898_bib0007","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","article-title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2025.100898_bib0008","doi-asserted-by":"crossref","first-page":"563","DOI":"10.21037\/tlcr.2016.10.16","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future","volume":"5","author":"Proto","year":"2016","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.ctarc.2025.100898_bib0009","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2025.100898_bib0010","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1158\/1078-0432.CCR-19-1871","article-title":"Preclinical comparison of the blood-brain barrier permeability of osimertinib with other EGFR TKIs","volume":"27","author":"Colclough","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2025.100898_bib0011","unstructured":"U.S. Food and Drug Administration. FDA approves osimertinib for first-line treatment of metastatic NSCLC with most common EGFR mutations, 2018."},{"issue":"4","key":"10.1016\/j.ctarc.2025.100898_bib0012","doi-asserted-by":"crossref","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","article-title":"Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Riely","year":"2024","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.ctarc.2025.100898_bib0013","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2025.100898_bib0014","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1002\/ijc.33904","article-title":"Overall survival benefit of osimertinib and clinical value of upfront cranial local therapy in untreated EGFR-mutant nonsmall cell lung cancer with brain metastasis","volume":"150","author":"Zhao","year":"2022","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ctarc.2025.100898_bib0015","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11523-021-00794-6","article-title":"Osimertinib versus comparator EGFR TKI as first-line treatment for EGFR-mutated advanced NSCLC: FLAURA China, a randomized study","volume":"16","author":"Cheng","year":"2021","journal-title":"Target. Oncol."},{"key":"10.1016\/j.ctarc.2025.100898_bib0016","doi-asserted-by":"crossref","first-page":"e746","DOI":"10.1634\/theoncologist.2019-0647","article-title":"Real-world evidence in oncology: opportunities and limitations","volume":"25","author":"Di Maio","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.ctarc.2025.100898_bib0017","unstructured":"U.S. Food and Drug Administration. Oncology real world evidence program. Vol 2022. Rockville, MD, 2021."},{"key":"10.1016\/j.ctarc.2025.100898_bib0018","unstructured":"United States Census Bureau. 2010 Census regions and divisions of the United States. Vol 2019."},{"key":"10.1016\/j.ctarc.2025.100898_bib0019","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med. Care"},{"year":"2014","series-title":"Division of Cancer Control & Population Sciences","key":"10.1016\/j.ctarc.2025.100898_bib0020"},{"key":"10.1016\/j.ctarc.2025.100898_bib0021","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1634\/theoncologist.2020-0011","article-title":"Real-world treatment patterns and progression-free survival associated with anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor therapies for ALK+ non-small cell lung cancer","volume":"25","author":"Jahanzeb","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.ctarc.2025.100898_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.19.00013","article-title":"Characterizing the feasibility and performance of real-world tumor progression end points and their association with overall survival in a large advanced non-small-cell lung cancer data set","volume":"3","author":"Griffith","year":"2019","journal-title":"JCo Clin. Cancer Inform."},{"key":"10.1016\/j.ctarc.2025.100898_bib0023","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/annonc\/mdz060","article-title":"Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer","volume":"30","author":"Blumenthal","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2025.100898_bib0024","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/j.ijrobp.2020.07.1306","article-title":"Different efficacy of Osimertinib for EGFR Exon 19del or L858R in NSCLC patients with brain metastases","volume":"108","author":"Li","year":"2020","journal-title":"Int. J. Radiat. Oncol.*Biol.*Phys."},{"key":"10.1016\/j.ctarc.2025.100898_bib0025","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.2147\/CMAR.S207170","article-title":"Impact of EGFR genotype on the efficacy of osimertinib in EGFR tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study","volume":"11","author":"Igawa","year":"2019","journal-title":"Cancer Manage Res."},{"key":"10.1016\/j.ctarc.2025.100898_bib0026","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.3390\/cancers12082311","article-title":"Time to next treatment as a meaningful endpoint for trials of primary cutaneous lymphoma","volume":"12","author":"Campbell","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctarc.2025.100898_bib0027","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.17547","article-title":"Correlation between surrogate end points and overall survival in a multi-institutional clinicogenomic cohort of patients with non-small cell lung or colorectal cancer","volume":"4","author":"Kehl","year":"2021","journal-title":"JAMa Netw. Open"},{"key":"10.1016\/j.ctarc.2025.100898_bib0028","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1002\/cncr.32383","article-title":"Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer","volume":"125","author":"Khozin","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.ctarc.2025.100898_bib0029","first-page":"1","article-title":"Real-world treatment patterns of metastatic non-small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors","volume":"00","author":"Shenolikar","year":"2022","journal-title":"Cancer Med."},{"key":"10.1016\/j.ctarc.2025.100898_bib0030","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.lungcan.2018.08.003","article-title":"Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: a phase II single-arm trial","volume":"124","author":"Lim","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctarc.2025.100898_bib0031","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.lungcan.2013.05.019","article-title":"EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lung","volume":"81","author":"Conforti","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctarc.2025.100898_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100280","article-title":"Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies","volume":"6","author":"Di Noia","year":"2021","journal-title":"ESMo Open"},{"key":"10.1016\/j.ctarc.2025.100898_bib0033","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s11523-019-00644-6","article-title":"Clinical modality of resistance and subsequent management of patients with advanced non-small cell lung cancer failing treatment with Osimertinib","volume":"14","author":"Mu","year":"2019","journal-title":"Target. Oncol"},{"key":"10.1016\/j.ctarc.2025.100898_bib0034","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejca.2021.09.041","article-title":"Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT)","volume":"159","author":"Sakata","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ctarc.2025.100898_bib0035","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/onco.13951","article-title":"First-line Osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: outcome and safety in the real world: FLOWER study","volume":"27","author":"Lorenzi","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.ctarc.2025.100898_bib0036","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with Osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2025.100898_bib0037","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-006531","article-title":"Treatment crossovers in time-to-event non-inferiority randomised trials of radiotherapy in patients with breast cancer","volume":"4","author":"Parpia","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.ctarc.2025.100898_bib0038","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.jval.2014.06.006","article-title":"Analyzing overall survival in randomized controlled trials with crossover and implications for economic evaluation","volume":"17","author":"J\u00f6nsson","year":"2014","journal-title":"Value Health"},{"key":"10.1016\/j.ctarc.2025.100898_bib0039","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1177\/09622802211017592","article-title":"Impact of unequal censoring and insufficient follow-up on comparing survival outcomes: applications to clinical studies","volume":"30","author":"Srivastava","year":"2021","journal-title":"Stat. Methods Med. Res."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246829422500036X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246829422500036X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T15:07:48Z","timestamp":1754060868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S246829422500036X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":39,"alternative-id":["S246829422500036X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.100898","relation":{},"ISSN":["2468-2942"],"issn-type":[{"type":"print","value":"2468-2942"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world comparative outcomes of EGFR-TKIs for first-line treatment of EGFR+ metastatic non\u2013small-cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.100898","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100898"}}